Kornimate/medical-research-clean huggingface dataset:
effects of t-bet b cells in persistent virus control after discontinuance of nas in chb patients

Conditions: Chronic HBV Infection; Drug Withdrawal

Summary: the immune mechanism of the nucleos(t)ide analogs (nas) in inhibiting hbv replication effectively while having a low sustained virus control rate after drug withdrawal is unclear. b cell immunity and antibody response are the keys to prevent hbv reinfection and keep the virus under control. t-bet+ b, which can be regulated by il-21, is a newly discovered major effector b cell in protection of pathogens and it is a main subtype of hbsag-specific b cells. thus, we suspect that t-bet+ b may play a role in ongoing controlling of the virus after withdraw of nas in chb patient. based on our previous studies on chb immunity, we use the rnaseq analyse, flow cytometry, and elispot assay to analyze the frequency, function, and phenotype of b cells in chb patients with different profiles after withdraw of nas.


Eligibility criteria:
inclusion criteria: 18 to 70 years old, no gender restriction, serum hbsag positive than 6 months, can understand and sign informed consent, good compliance. exclusion criteria: coinfected with other hepatotropic virus such as hepatitis c virus,hepatitis d -virus,hepatitis e and hepatitis a etc; coinfected with hiv, markers such as ceruloplasmin, anti-nuclear antibodies and anti-mitochondrial antibodies for co-existent autoimmune and metabolic liver diseases were positive, with hepatocellular carcinoma(hcc) with uncontrollable extrehepatic disease, received glucocorticoid or other immune inhibitor therapy, pregnancy

Keywords: transcription factor bet chronic hepatitis b nucleotide analogs function cure b cell
pentoxifylline and lumbar radiculopathy

Conditions: Lumbar Radiculopathy; Lumbar Disc Herniation; Lumbar Disc Disease

Summary: the objective of this prospective controlled crossover study is to evaluate the efficacy and safety of pentoxifylline per os (800 mg daily) in the management of lumbar radiculopathy

patients with lumbar radiculopathy, are recruited from senior author clinic. after verification of inclusion and exclusion criteria, patients consenting to enter the study are given 2 sequences (order randomly assigned) of treatment: ibuprofen 600 mg bid, with paracetamol 1000 mg tid, pregabalin 75 mg bid for 15 days with pentoxifylline and 15 days without it. basic clinical and demographical data are noted. lumbar mri results are also noted. clinical evaluation of the patient is performed and included: clinical examination (including motor exam of lower limbs); pain is assessed according to numerical rating scale (nrs), and relative percentage of global improvement.

Eligibility criteria:
inclusion criteria: * unilateral lumbar radiculopathy * disc hernia confirming the diagnosis with radio-clinical concordance exclusion criteria: * radicular deficit needing surgery * cauda equine syndrome * absence of radio-clinical concordance on mri * contraindication for anti-inflammatory (hypertension, renal insufficiency, gastric ulcer ...) * previous intolerance to pentoxifylline, and/or to pregabalin and/or paracetamol * pregnancy * follow-up not possible * hepatic dysfunction * history of drug abuse * current use of tramadol, codeine and/or morphine and its derivative * antidepressant use

Keywords: pentoxifylline disc hernia sciatica lumbar radiculopathy
efficacy of intralesional platelet rich plasma in patients of de quervain's tenosynovitis

Conditions: De Quervain Tenosynovitis

Summary: de quervain's tenosynovitis (dqt) was originally identified by swiss surgeon fritz de quervain in 1895. it is a condition involving the entrapment of tendons within the first dorsal compartment of the wrist. in dqt, the sheaths surrounding the abductor pollicis longus (apl) and extensor pollicis brevis tendons thicken as they pass through a fibro-osseous tunnel near the radial styloid of the distal wrist. this thickening leads to pain, which worsens with thumb movements and radial or ulnar deviation of the wrist. traditional treatment methods, such as corticosteroid injections and physical therapy, often provide only temporary relief and may not address the underlying inflammation effectively. intralesional platelet rich plasma (prp) therapy has emerged as a promising alternative, utilizing the patient's own growth factors and cytokines to promote healing and reduce inflammation. by investigating the efficacy of intralesional prp in patients with dqt, this research aims to provide evidence for a minimally invasive treatment option that could enhance recovery times, reduce pain, and improve functional outcomes.


Eligibility criteria:
inclusion criteria: * either gender, * aged between 18 and 60 years * presenting with de quervain's tenosynovitis exclusion criteria: * previous surgery or intervention forde quervain's tenosynovitis * local skin infection or osteomyelitis * pregnant or lactating mothers
a study to evaluate the safety, tolerability, and effects of anatabloc® crème in rosacea

Conditions: Rosacea

Summary: this is a multi-site, four-visit, eight-week, double-blind, randomized, vehicle-controlled, parallel-group study followed by an eight-week open-label extension to evaluate the safety, tolerability, and potential effects of anatabloc facial cream. the secondary aim is to evaluate if anatabloc facial cream improves the appearance of the skin in subjects with mild to moderate rosacea.


Eligibility criteria:
inclusion criteria: * age between 25-70 years * diagnosed with mild to moderate rosacea exclusion criteria: * allergy or sensitivity to the study products or their components * severe rosacea * current use of glucocorticoids, anti-acne products, antibiotics, topical retinoids, or vasoactive drugs * recent oral isotretinoin use * current use of anatabine-containing supplements (ie. anatabloc, anatabloc unflavored, cigrx)

Keywords: rosacea anatabine anatabloc dermatology
fluorescence guided minimally-invasive resection of abdominal paragangliomas using indocyanine green

Conditions: Paraganglioma

Summary: this study is exploring whether it's possible to detect paragangliomas (a rare type of tumor) during minimally invasive surgery by using a technique called near-infrared fluorescence imaging, guided by a substance called indocyanine green (icg). the goal is to see if this method can help surgeons identify and treat paragangliomas more accurately and during minimally invasive procedures.


Eligibility criteria:
inclusion criteria: * diagnosed with abdominal paraganglioma and underwent minimally-invasive surgical resection exclusion criteria: * open surgical procedures

Keywords: fluorescence guided surgery
sintilimab and bevacizumab combined with radiotherapy for advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to investigate both the efficacy and safety of sintilimab combined with bevacizumab and radiotherapy in advanced hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: 1. age 18-75 years; 2. eastern cooperative oncology group (ecog) performance status score of 0 or 1; 3. treatment-naïve primary hcc (consistent with the american association for the study of liver diseases 2018 guideline on liver cancer diagnosis (18)) or initial recurrent hcc after radical resection without any postoperative anti-cancer treatment; 4. at least one measurable lesion in the liver on the basis of modified response evaluation criteria in solid tumors (mrecist); 5. presented with cheng's type i/ii/iii pvtt; 6. largest tumor size ≤ 10 cm, number of tumors ≤ 3, and remnant liver volume ≥ 50%; 7. child-pugh class a; 8. adequate hematological, liver, renal function: 1. hemoglobin concentration ≥ 90 g/l; 2. neutrophil count ≥ 1.5×109/l; 3. platelet count ≥ 60×109/l; 4. ast and alt ≤ 3×upper limit of normal (uln) 5. total bilirubin ≤ 1.5×uln; 6. serum creatinine ≤ 1.5×uln; 7. serum albumin concentration ≥ 30 g/l; 9. life expectancy of at least 3 months. exclusion criteria: 1. tumor invasion of the superior mesenteric vein or bile ducts; 2. infiltrative hcc; 3. allergic to research reagents; 4. with other malignancies within 5 years; 5. with poorly controlled hypertension; 6. a past medical history of hepatic decompensation, such as hepatic encephalopathy, refractory ascites, and esophageal or gastric variceal bleeding; 7. a history of autoimmune disease; 8. active infection requiring systemic treatments; 9. severe bleeding; 10. with diseases needing daily non-steroidal anti-inflammatory drug (nsaid) therapy; 11. with other severe comorbidities.
reperfuse ischemic vessels with endovascular recanalization device in japan (river japan)

Conditions: Acute Ischemic Stroke

Summary: the main objective of this study is to document that the thrombectomy catheter (rev-01) is effective and safe when used for revascularization in subjects with acute ischemic stroke within 8 hours of symptom onset who are ineligible for treatment with iv t-pa, or in whom treatment with iv t-pa has been ineffective.


Eligibility criteria:
key inclusion criteria: * subject presenting with clinical signs and symptoms consistent with a diagnosis of acute ischemic stroke * onset of symptom is within 8 hours prior to treatment with rev-01 * treatment with iv t-pa is ineligible or ineffective * occluded (presenting tici score of 0 or 1) m1 or m2 of mca, basilar or vertebral artery, or intracranial segment of ica, confirmed by angiography that it is accessible to the rev-01 * nihss score is 8-30 * prior to new focal disabling neurologic deficit, mrs score was 0-2 * age from 20 y.o. to 85 y.o. * written informed consent to participate by subject or legal representative key exclusion criteria: * subject presenting; ica dissection, angiitis, arterial tortuosity that would prevent the device from reaching the target vessel, arterial stenosis \> 50% that would prevent the device from reaching the target vessel, evidence of acute intracranial hemorrhage, evidence of mass effect or intracranial tumor, evidence of extended early ischemic changes * subject with more than two major artery occluded * known sensitivity or ineligible to radiographic agent, or metallic allergy * administration of dabigatran or heparin within 48 hours preceding the onset of stroke and have an elevated aptt or ptt above twice of the normal range for the laboratory at presentation * known bleeding diathesis of current use of oral anticoagulants (e.g., warfarin sodium) with international normalized ration (inr) \> 3 * platelet count \< 30,000/mm3 * glucose \< 50 mg/dl * severe sustained hypertension (sbp \> 185mmhg or dbp \> 110mmhg) refractory to pharmacological management * life expectancy of less than 90 days * pregnancy or females who are lactating * current participation in an investigational drug or device study * otherwise determined by investigator to be medically unsuitable for participation

Keywords: ischemia stroke ischemic stroke thrombectomy brain clot cerebrovascular disease recanalization revascularization clot retriever neurovascular intervention interventional neuroradiology neurovascular clinical trial
a first in human (fih) study of ibi356 in healthy participants and in atopic dermatitis patients

Conditions: Healthy Participants; Atopic Dermatitis Patients

Summary: the purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of ibi356 in healthy participants and in atopic dermatitis patients


Eligibility criteria:
inclusion criteria: 1. healthy participants: 1. aged 18 to 45 years, 2. weight 50 to 120 kgs, 3. good physical and mental health based on medical history, physical examination, clinical laboratory, ecg, and vital signs, as judged by the investigator. 4. no child-bearing potential during the trial and within 6 months after sad doses, and adequate contraceptive measures can be taken. 2. atopic dermatitis: 1. aged 18 to 75 years, 2. body mass index (bmi): 18.0 - 32.0 kg/m2, 3. atopic dermatitis (ad) for 1 year or longer at baseline, 4. eczema area and severity index (easi) of 16 or higher at baseline, 5. investigator global assessment (iga) of 3 or 4 at baseline, 6. ad involvement of 10 percent or more of body surface area at baseline, 7. documented history, within 1 year before baseline, of either inadequate response to topical treatments or inadvisability of topical treatments, 8. must have applied a stable dose of topical bland emollient at least twice daily for at least 7 consecutive days before baseline. exclusion criteria: 1. history of relevant drug allergies. 2. has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments 3. healthy participants: 1. history of alcohol abuse or drug addiction within 1 year before screen, 2. positive drug and alcohol screen at screening. 4. atopic dermatitis: 1. having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, was likely to require immunosuppressive/ immunomodulating drugs treatment(s) during the first 4 weeks of study treatment: 2. treatment with topical corticosteroids (tcs) or topical calcineurin inhibitors (tci) within 1 week before the baseline visit.
mdr - longevity it oblique and offset liners

Conditions: Non-inflammatory Degenerative Joint Disease (NIDJD); Avascular Necrosis; Protrusio Acetabuli; Traumatic Arthritis; Slipped Capital Femoral Epiphyses; Fracture of the Pelvis; Diastrophic Variant; Osteoarthritis; Fused Hip

Summary: the objective of this retrospective enrollment/prospective follow-up consecutive series pmcf study is to collect data confirming safety, performance, and clinical benefits of the longevity it oblique and offset liners when used for primary or revision total hip arthroplasty (implants and instrumentation) at a minimum of 10-year follow-up.

the objective of this retrospective enrollment/prospective follow-up consecutive series pmcf study is to collect data confirming safety, performance, and clinical benefits of the longevity it oblique and offset liners when used for primary and revision total hip arthroplasty (implants and instrumentation) at 1, 3, 5, 7, and 10 years\*. the subject devices have been on the market since 2010 but have insufficient data to support 10 years of clinical history. a prospective aspect to the study will be utilized to collect long-term data.

Eligibility criteria:
inclusion criteria: * study devices must have been implanted following the appropriate surgical technique and ifu * patient must be 18 years of age or older * patient must be willing and able to sign or verbally consent using the irb approved informed consent * patient must have undergone primary or revision hip arthroplasty with the longevity it oblique and/or offset liners according to a cleared indication, which includes the following: * noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis, protrusio acetabuli, traumatic arthritis, slipped capital, epiphysis, fused hip, fracture of the pelvis, and diastrophic variant * revision where other devices or treatments have failed * patient must have reached full skeletal maturity exclusion criteria: * off-label use of study devices * osteoradionecrosis * neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation * systemic or local infection * uncooperative patient or patient with neurologic disorders who is incapable of following directions * patient is known to be pregnant or nursing * patient is a prisoner * patient is a known alcohol or drug abuser * patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent
a study of the revlite laser system for the treatment of refractory mixed type melasma

Conditions: Melasma

Summary: the purpose of this study is to compare a hydroquinone skin care regimen alone to a combination of revlite laser treatment with a hydroquinone skin care regimen for the treatment of melasma.


Eligibility criteria:
inclusion criteria: * subjects with fitzpatrick skin type iii-vi * subjects with mixed (epidermal and dermal) type melasma diagnosed by wood's lamp. * subjects who are over the age of 18 years of age * the subject is willing and able to comply with study instructions and return to the clinic for required visits. * the subject's melasma has persisted for greater than 6 months exclusion criteria: * the subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. * the subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis. * the subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy. * the subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy). * the subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study. * the subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study. * the subject has used photosensitizing drugs (e.g., declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present. * the subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial. * the subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate). * the subject has diabetes type 1 or 2. * the subject has a sensitivity to hydroquinone or retin-a. * the subject has evidence of a compromised immune system or hepatitis. * has had microdermabrasion in past 3 months, other laser or intense pulsed light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks. * has a history of keloids or hypertrophic scarring * has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study
phenylbutyrate response as a biomarker for alpha-synuclein clearance from the brain

Conditions: Parkinson's Disease

Summary: this is a phase i clinical trial of the fda approved drug glycerol phenylbutyrate to see if phenylbutyrate can increase the removal of alpha-synuclein from the brain into the bloodstream. alpha-synuclein forms abnormal protein deposits in dopamine neurons and is believed to cause the death of brain cells, leading to parkinson's disease.

this is a phase i clinical trial of phenylbutyrate in 20 parkinson patients and 20 age- and sex-matched normal control subjects to see if phenylbutyrate can increase the removal of alpha-synuclein from the brain into the bloodstream. all subjects will receive 20 grams/day of phenylbutyrate in the liquid form phenylbutyrate-triglyceride taken as one teaspoonful three times per day with meals. blood will be drawn on two days prior to starting phenylbutyrate to measure alpha-synuclein concentrations. phenylbutyrate-triglyceride will then be started and the change in plasma alpha-synuclein will be measured on day 1, 7, 14, and 21 days while taking phenylbutyrate. after 21 days, the drug will be stopped and a final blood sample will be measured at 28 days to see if plasma alpha-synuclein has fallen to its pre-phenylbutyrate level. no effects on parkinson symptoms are expected during this short trial. please note that although taking any type of parkinson's drugs for symptomatic treatment disqualifies you, if you and your neurologist are willing and able to have you off parkinson medication for six weeks before and during the trial, you may be eligible to participate.

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease with mild symptoms; * may be on treatment with dopamine agonists provided that the treating neurologist agrees: 1. that the drugs can be stopped for at least three weeks prior to participating in the phenylbutyrate study, and 2. for the 4-week duration of the study. * age and sex matched normal control subjects from spouses and the general population; * in good general health; * controlled hypertension, or * controlled hypercholesterolemia with medication. exclusion criteria: * pregnant women; * current treatment with: 1. l-3,4-dihydroxyphenylalanine (l-dopa); 2. monoamine oxidase (mao) inhibitors, 3. catechol-o-methyl transferase (comt) inhibitors; 4. histone deacetylase (hdac) inhibitors; 5. prednisone or other corticosteroids, or 6. probenecid. * severe cardiopulmonary disease such as: 1. congestive heart failure, or 2. emphysema requiring supplemental oxygen; * renal disease with serum creatinine greater than 2.5; * history of: 1. depression in the prior year; 2. epilepsy; 3. stroke; 4. prior brain surgery; 5. dementia, or 6. psychosis.